CD8+ T cells with parasite-specific cytotoxic activity and a Tc1 profile of cytokine and chemokine secretion develop in experimental visceral leishmaniasis

Parasite Immunology

Volumn 25, Issue 11-12, 2003, Pages 569-579

  Tsagozis, Panagiotis ^a   Karagouni, Evdokia ^a   Dotsika, Eleni ^a  

^a HELLENIC PASTEUR INSTITUTE   (Greece)

Author keywords

CD8; Chemokines; Cytokines; Cytotoxicity; Leishmania

Indexed keywords

BETA ACTIN; CD8 ANTIGEN; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCLONAL ANTIBODY; RANTES; RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EXPERIMENTAL MODEL; FLOW CYTOMETRY; LEISHMANIASIS; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PARASITISM; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VISCERAL LEISHMANIASIS;

ANIMALS; APOPTOSIS; BASE SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINES; CYTOKINES; DNA, COMPLEMENTARY; FEMALE; GENE EXPRESSION; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES, CYTOTOXIC;

ANIMALIA; LEISHMANIA INFANTUM; MURINAE; PROTOZOA;

EID: 1842586922     PISSN: 01419838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0141-9838.2004.00672.x     Document Type: Article

References (40)

1. Herwaldt BL. Leishmaniasis. Lancet 1999; 354: 1191-1199.
2. Murray HW, Stern JJ, Weite K, Rubin BY, Carriero SM & Nathan CF. Experimental visceral leishmaniasis production of interleukin 2 and interferon-γ, tissue immune reaction, and response to treatment with interleukin 2 and interferon-γ. J Immunol 1987; 138: 2290-2297.
3. Miralles GD, Stoeckle MY, McDermott DF, Finkelman FD & Murray HW. Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect Immun 1994; 62: 1058-1063.
4. Vidal S, Tremblay ML, Govoni G et al. The Ity/Lsh/Bcg locus: natural resistance to infection with intracellular parasites is abrogated by disruption of the Nrampl gene. J Exp Med 1995; 182: 655-666.
5. Bradley DJ, Taylor BA, Blackwell J, Evans EP & Freeman J. Regulation of Leishmania populations within the host. III. Mapping of the locus controlling susceptibility to visceral leishmaniasis in the mouse. Clin Exp Immunol 1979; 37: 7-14.
6. + cells in experimental visceral leishmaniasis. J Immunol 1988; 141: 3971-3977.
7. McElrath MJ, Murray HW & Cohn ZA. The dynamics of granuloma formation in experimental visceral leishmaniasis. J Exp Med 1988; 167: 1927-1937.
8. Murray HW, Miralles GD, Stoeckle MY & McDermott DF. Role and effect of IL-2 in experimental visceral leishmaniasis. J Immunol 1993; 151: 929-937.
9. Lehmann J, Enssle KH, Lehmann I, Emmendörfer A & Lohmann-Matthes ML. The capacity to produce IFN-γ rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice. J Interferon Cytokine Res 2000; 20: 63-77.
10. + T cell effector mechanisms in resistance to infection. Annu Rev Immunol 2000; 18: 275-308.
11. Alexander CE, Kaye PM & Engwerda CR. CD95 is required for the early control of parasite burden in the liver of Leishmania donovani-infecled mice. Eur J Immunol 2001; 31: 1199-1210.
12. Conceição-Silva F, Perlaza B, Louis JA & Romero P. Leishmania major infection in mice primes for specific major histocompatibility complex class-I restricted cytotoxic T cell responses. Eur J Immunol 1994; 24: 2813-2817.
13. Murray HW, Spitalny GL & Nathan CF. Activation of mouse peritoneal macrophages in vitro and in vivo by interferon-gamma. J Immunol 1985; 134: 1619-1622.
14. Tumang MCT, Keogh C, Moldawer LL et al. Role and effect of TNF-α in experimental visceral leishmaniasis. J Immunol 1994; 153: 768-775.
15. Murray HW, Jungbluth A, Ritter E, Montelibano C & Marino MW. Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment. Infect Immun 2000; 68: 1428-1434.
16. Liew FY, Li Y & Millott S. Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the action of nitric oxide. J Immunol 1990; 145: 4306-4310.
17. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992; 10: 411-452.
18. Mackay CR. Chemokines: immunology's high impact factors. Nat Immunol 2001; 2: 95-101.
19. Brandonisio O, Panaro MA, Fumarola I et al. Macrophage chemotactic protein-1 and macrophage inflammatory protein-1 alpha induce nitric oxide release and enhance parasite killing in Leishmania infantum-infected human macrophages. Clin Exp Med 2002; 2: 125-129.
20. Marsden VS & Strasser A. Control of apoptosis in the immune system. Bcl-2, BH3-only proteins and more. Annu Rev Immunol 2003; 21: 71-105.
21. Berent RL, Brun R & Kressne SM. A simple monophasic medium for axenic culture of hemoflagellates. J Parasitol 1976; 62: 360-365.
22. Titus RG, Marchand M, Boon T & Louis JA. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol 1985; 7: 545-555.
23. Papadopoulou G, Karagouni E & Dotsika E. ISCOMs vaccine against experimental leishmaniasis. Vaccine 1998; 16: 885-892.
24. Sambhara SR, Upadhy AG & Miller RG. Generation and characterization of peptide-specific, MHC-restricted cytotoxic T-lymphocyte (CTL) and helper T cell lines from unprimed T cells under microculture conditions. J Immunol Meth 1990; 130: 101-109.
25. Bisti S, Konidou G, Papageorgiou F, Milon G, Bolaert JR & Soteriadou K. The outcome of Leishmania major experimental infection in BALB/c mice can be modulated by exogenously delivered iron. Eur J Immunol 2000; 30: 3732-3740.
26. + T cells activated in a graft-versus-host reaction. J Immunol 1990; 145: 2167-2176.
27. Van Pinxteren LAH, Cassidy JP, Smedegaard BHC, Agger EM & Andersen P. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 2000; 30: 3689-3698.
28. Houde M, Bertholet S, Gagnon E et al. Phagosomes are competent organelles for antigen cross-presentation. Nature 2003; 425: 402-406.
29. + cytotoxic T cells and Leishmania-infected macrophages. J Exp Med 1991; 174: 499-505.
30. Conceição-Silva F, Hahne M, Schroter M, Louis J & Tschopp J. The resolution of lesions induced by Leishmania major in mice requires a functional Fas (APO-1, CD95) pathway of cytotoxicity. Eur J Immunol 1998; 28: 237-245.
31. + cytotoxic T lymphocytes and natural killer cells: participation of Fas ligand in granule exocytosis model of cytotoxicity. Biochem Biophys Res Commun 2002; 296: 328-336.
32. Reiner SL & Locksley RM. The regulation of immunity to Leishmania major. Annu Rev Immunol 1995; 13: 151-177.
33. Taylor A & Murray HW. Intracellular antimicrobial activity in the absence of interferon-γ effect of interleukin-12 in experimental visceral leishmaniasis in interferon-γ gene disrupted mice. J Exp Med 1997; 185: 1231-1239.
34. Cotterell SE, Engwerda CR & Kaye PM. Leishmania donovani infection initiates T cell-independent chemokine responses, which are subsequently amplified in a T cell-dependent manner. Eur J Immunol 1999; 29: 203-214.
35. Sato N, Kuziel WA, Melby PC et al. Defects in the generation of IFN-gamma are overcome to control infection with Leishmania donovani in CC chemokine receptor (CCR) 5-, macrophage inflammatory protein-1 alpha-, or CCR2-deficient mice. J Immunol 1999; 163: 5519-5525.
36. Dorner BG, Scheffold A, Rolph MS, Huser MB et al. MIP-1alpha, MIP-1beta, RANTES, and ATAC/lymphotactin function together with IFN-gamma as type 1 cytokines. Proc Natl Acad Sci 2002; 99: 6181-6186.
37. + T cells into cytotoxic T cells secreting Th1 or Th2 cytokines. Immunity 1995; 2: 271-279.
38. Erard F, Garcia-Sanz JA, Morrigl R & Wild MT. Presence or absence of TGF-beta determines IL-4-induced generation of type 1 or type 2 CD8 T cell subsets. J Immunol 1999; 162: 209-214.
39. Murray HW, Hariprashad J, Aguero B, Arakawa T & Yeganegi H. Antimicrobial response of a T cell-deficient host to cytokine therapy: effect of interferon-gamma in experimental visceral leishmaniasis in nude mice. J Infect Dis 1995; 171: 1309-1316.
40. Murray HW & Hariprashad J. Interleukin 12 is effective treatment for an established systemic intracellular infection: experimental visceral leishmaniasis. J Exp Med 1995; 181: 387-391.